Epstein-Barr virus latent membrane protein 1 and 2 peptides presented on MHC class I (EBV LMP1/2-MHC I)

The target consists of peptide fragments derived from the Epstein-Barr virus (EBV) Latent Membrane Protein 1 (LMP1) and Latent Membrane Protein 2 (LMP2) presented on the cell surface by Major Histocompatibility Complex (MHC) class I molecules (Taylor et al., 2015). LMP1 and LMP2 are key viral proteins expressed during EBV latency phases II and III, which are associated with various malignancies including nasopharyngeal carcinoma and Hodgkin lymphoma (Young & Rickinson, 2004). LMP1 functions as a constitutively active mimic of the CD40 receptor, promoting cell survival and proliferation, while LMP2A mimics B-cell receptor signaling to maintain viral latency (Longnecker, 2000). Because these proteins are intracellular, they are processed into short peptides and presented on MHC class I for recognition by CD8+ cytotoxic T lymphocytes (Bollard & Heslop, 2016). This peptide-MHC complex is a primary target for EBV-specific T-cell therapies, particularly in patients with post-transplant lymphoproliferative disorder (PTLD) (Prockop et al., 2020). Therapeutic strategies include adoptive T-cell therapies, such as Tabelecleucel, which utilize T cells to selectively eliminate cells presenting these viral epitopes (Atara Biotherapeutics, 2022). Challenges in targeting this complex include potential immune escape through HLA downregulation and the need for HLA-matching in allogeneic therapies (Hislop et al., 2007).

Other names

LMP1/2-HLA complexEBV LMP peptide-MHC complexLatent membrane protein 1 and 2-MHC class I complexEBV-specific peptide-MHC

Recognition of the peptide-MHC complex by specific T-cell receptors (TCRs) on cytotoxic T lymphocytes, leading to the release of perforins and granzymes and subsequent lysis of the target cell.